1 July 2024
Belluscura plc
("Belluscura" or the "Company")
Total Voting Rights
Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that the total number of Ordinary Shares in the capital of the Company in issue is 167,032,567 with each Ordinary Share carrying the right to one vote. There are no Ordinary Shares held in treasury and therefore the total number of voting rights in the Company is 167,032,567. The above figure may be used by Shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
For further information, please contact:
| Belluscura plc | www.belluscura.com |
| Robert Rauker, Chief Executive Officer | via MHP |
| Simon Neicheril, Chief Financial Officer |
|
|
|
|
| SPARK Advisory Partners Limited | Tel: +44 (0)20 3368 3550 |
| Neil Baldwin / Jade Bayat |
|
|
|
|
| Dowgate Capital Limited | Tel: +44 (0)20 3903 7715 |
| James Serjeant / Russell Cook / |
|
|
|
|
| MHP Communications | Tel: +44 (0)20 3128 8100 / +44 7884 494112 |
| Katie Hunt / Matthew Taylor |
|
|
|
|
About Belluscura plc ( www.belluscura.com )
Belluscura is a UK medical device company focused on developing high performing, lightweight and portable oxygen enrichment technology used in a broad range of industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health, mobility and economic outcomes for patients, healthcare providers and insurance organisations.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
